Published November 19, 1999 | Version public
Journal Article

Formation of Indigo by Recombinant Mammalian Cytochrome P450

  • 1. ROR icon University of Queensland
  • 2. ROR icon Vanderbilt University
  • 3. ROR icon California Institute of Technology
  • 4. ROR icon National Institute of Public Health

Abstract

The development of bicistronic systems for coexpression of recombinant human cytochrome P450 enzymes (P450s) with their redox partner, NADPH-cytochrome P450 reductase (NPR), has enabled P450 activity to be reconstituted within bacterial cells. During expression of recombinant P450 2E1 and some other forms, we observed the formation of a blue pigment in bacterial cultures. The pigment was extracted from cultures and shown to comigrate with standard indigo on TLC. UV-visible spectroscopy and mass spectrometric analysis provided further support for identification of the pigment as indigo. Indigo is known to form following the spontaneous oxidation of 3-hydroxyindole. Accordingly, we speculated that indole, formed as a breakdown product of tryptophan in bacteria, was hydroxylated by the P450 system, leading to indigo formation. Bacterial membranes containing recombinant P450 2E1 and human NPR were incubated in vitro with indole and shown to catalyze formation of a blue pigment in a time- and cofactor-dependent manner. These studies suggest potential applications of mammalian P450 enzymes in industrial indigo production or in the development of novel colorimetric assays based on indole hydroxylation.

Additional Information

© 1999 Academic Press. Received 5 October 1999. This work was supported in part by National Health and Medical Research Council (Australia) Grant 951135 and Australian Research Council Grant A09937199 (E.M.J.G.), Maxygen Corp. (F.H.A.), Grant IGA 1850-5 of the Internal Grant Agency of the Czech Ministry of Health (P.S.), and Grants R35 CA44353 and P30 ES00267 from the National Institutes of Health (F.P.G.).

Additional details

Identifiers

Eprint ID
89100
DOI
10.1006/bbrc.1999.1702
Resolver ID
CaltechAUTHORS:20180823-144310509

Related works

Describes
10.1006/bbrc.1999.1702 (DOI)

Funding

National Health and Medical Research Council (NHMRC)
951135
Australian Research Council
A09937199
Maxygen Corporation
Czech Ministry of Health
IGA 1850-5
NIH
R35 CA44353
NIH
P30 ES00267

Dates

Created
2018-08-23
Created from EPrint's datestamp field
Updated
2021-11-16
Created from EPrint's last_modified field